`
`
`
`
`
`Case No. IPR2018-00272
`Patent No. 9,393,208
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`MYLAN PHARMACEUTICALS INC.
`Petitioner
`
`v.
`
`POZEN INC. and HORIZON PHARMA USA, INC.
`Patent Owners
`
`
`
`Case No. IPR2018-00272
`Patent No. 9,393,208
`
`
`
`
`
`
`
`PATENT OWNER'S EXHIBIT LIST
`
`
`
`
`
`Case No. IPR2018-00272
`Patent No. 9,393,208
`
`PATENT OWNER’S EXHIBIT LIST
`Description of Document
`
`Gabriel, S.E., et al., “Risk for Serious Gastrointestinal Complications
`Related to Use of Nonsteroidal Anti-inflammatory Drugs,” Annals of
`Internal Medicine, Vol. 115, No. 10, pp. 787-796 (1991) (“Gabriel”)
`Cryer, B. and Feldman, M., “Effects of Nonsteroidal Anti-
`inflammatory Drugs on Endogenous Gastrointestinal Prostaglandins
`and Therapeutic Strategies for Prevention and Treatment of
`Nonsteroidal Anti-inflammatory Drug-Induced Damage,” Archives of
`Internal Medicine, Vol. 152, pp. 1145-1155 (1992) (“Cryer”)
`Fries, J.F., et al., “Nonsteroidal Anti-Inflammatory Drug-Associated
`Gastropathy: Incidence and Risk Factor Models,” The American
`Journal of Medicine, Vol. 91, pp. 213-222 (1991) (“Fries”)
`U.S. Patent No. 9,220,698 Prosecution History Excerpt: Response to
`Final Office Action Mailed March 26, 2015 (Sept. 25, 2015)
`U.S. Patent No. 9,220,698 Prosecution History Excerpt: Advisory
`Action (Oct. 9, 2015)
`Exhibits Not Used
`
`Exhibit
`No.
`2001
`
`2002
`
`2003
`
`2004
`
`2005
`
`2006-
`2072
`2073
`
`Opinion & Order, filed on November 14, 2017 in Horizon Pharma,
`Inc. v. Dr. Reddy’s Laboratories, Inc., Civ. A. No. 2:15-cv-03324-
`SRC-CLW (SRC)
`2074 Memorandum of Mylan and DRL in Support of Their Motion for
`Summary Judgment of Invalidity of U.S. Patent Nos. 9,220,698 and
`9,393,208, filed on November 12, 2018 in Horizon Pharma, Inc. v.
`Dr. Reddy’s Laboratories, Inc., Civ. A. No. 2:15-cv-03324-SRC-
`CLW (SRC)
`Opinion, filed on November 19, 2018 in Horizon Pharma, Inc. v. Dr.
`Reddy’s Laboratories, Inc., Civ. A. No. 2:15-cv-03324-SRC-CLW
`(SRC)
`Final Judgment Under Rule 54(b), signed and filed January 22, 2019
`in Horizon Pharma, Inc. v. Dr. Reddy’s Laboratories, Inc., Civ. A.
`No. 2:15-cv-03324-SRC-CLW (SRC)
`Final Judgment Under Rule 54(b), signed and filed January 22, 2019
`in Horizon Pharma, Inc. v. Dr. Reddy’s Laboratories, Inc., Civ. A.
`No. 2:15-cv-03324-SRC-CLW (SRC)
`
`2075
`
`2076
`
`2077
`
`1
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Date: February 8, 2019
`
`COOLEY LLP
`ATTN: Patent Group
`1299 Pennsylvania Avenue,
`N.W Suite 700
`Washington, DC 20004-2400
`Tel: 720-566-4119
`Fax: 720-566-4099
`
`
`
`
`
`
`
`Case No. IPR2018-00272
`Patent No. 9,393,208
`
`Respectfully submitted,
`
`By: /Thomas A. Blinka/
`Thomas A. Blinka
`Reg. No. 44,541
`Counsel for Patent Owner
`
`2
`
`
`
`
`
`
`
`Case No. IPR2018-00272
`Patent No. 9,393,208
`
`CERTIFICATE OF SERVICE UNDER 37 C.F.R. § 42.6(e)
`
`I, Thomas A. Blinka, hereby certify that on this 8th day of February, 2019,
`
`the foregoing Patent Owner’s Exhibit List was served electronically via email on
`
`the following:
`
`Brandon M. White
`bmwhite@perkinscoie.com
`700 13th St., NW Suite 600
`Washington, DC 20005
`
`Emily Greb
`egreb@perkinscoie.com
`One East Main St., Suite 201
`Madison, WI 53703
`
`EsoNaproxen@perkinscoie.com
`
`Date: February 8, 2019
`
`
`
`By: /Thomas A. Blinka/
`Thomas A. Blinka
`Reg. No. 44,541
`Counsel for Patent Owner
`
`
`
`
`
`3
`
`